In particular, on the basis of the pre-clinical evidence that CX-5461 triggered synthetic lethality in tumor cells deficient for BRCA and resistant to PARP inhibitors [85], the compound has entered phase I clinical trials in 2016 for patients with solid tumors characterized by BRCA1/2 aberrations [85]. The gene discussed is BRCA1; the disease is neoplasm.